White Paper on How to Go Forward with Cell-Based Advanced Therapies in Europe

RG Erben, B Silva-Lima, I Reischl, G Steinhoff, G Tiedemann, W Dalemans, A (A.) de Vos, RTA Janssen, K Le Blanc, Gerjo van Osch, FP Luyten

Research output: Contribution to journalArticleAcademicpeer-review

27 Citations (Scopus)


The current White paper summarizes the discussions and exchange of experiences during the first European Interdisciplinary Summit on Cell-Based ATMPs held in Vienna, Austria, May 02-03, 2013. The meeting was supported by the Research Networking Programme REMEDIC (regenerative medicine) funded by the European Science Foundation and by the British Medical Research Council. To improve the competitiveness of Europe in the field of cell-based Advanced Medicinal Therapy Products (ATMPs), the following key issues were identified during the meeting: removal of national hurdles in the European Union, harmonization of national and subnational differences in Hospital Exemption rules, improved treatment algorithms for reimbursement, better knowledge on the mode of action, predictive preclinical efficacy and safety testing, need for innovative systems for preclinical testing, appropriate product characterization, manufacturing with cost of goods in mind, and appropriate design of clinical trials.
Original languageUndefined/Unknown
Pages (from-to)2549-2554
Number of pages6
JournalTissue Engineering Part A
Issue number19-20
Publication statusPublished - 2014

Research programs

  • EMC MM-01-51-01
  • EMC OR-01-62-02

Cite this